← Back to headlines
AstraZeneca's Imfinzi Combination Improves Survival in Bladder Cancer Study
AstraZeneca announced that its Imfinzi combination therapy demonstrated improved survival rates in a study for bladder cancer patients.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
